Gengraf Capsules and Ranolazine ER Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using cycloSPORINE and ranolazine together may increase the blood levels and effects of both. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications together. Contact your doctor if you experience potential signs and symptoms of excessive cycloSPORINE blood levels such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats, as these could be symptoms of a serious condition related to high levels of ranolazine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration of cyclosporine and ranolazine may increase the plasma concentrations of both drugs. Although the interaction has not been studied, competitive or noncompetitive inhibition of P-glycoprotein and CYP450 3A4 is possible, since these drugs are substrates as well as inhibitors of both the drug efflux transporter and isoenzyme. Drug toxicities may occur. Because ranolazine prolongs the QT interval in a dose-dependent manner, high plasma levels may increase the risk of ventricular arrhythmias including ventricular fibrillation and torsade de pointes.

MANAGEMENT: Caution is advised if cyclosporine and ranolazine are used in combination. Cyclosporine blood levels and renal function should be monitored more closely whenever ranolazine is added to or withdrawn from therapy, and the cyclosporine dosage adjusted as necessary. Similarly, pharmacologic response to ranolazine should be monitored more closely in patients who are stabilized on ranolazine and are starting or discontinuing cyclosporine. During concomitant treatment, patients should be advised to notify their physician if they experience signs and symptoms of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.

Gengraf Capsules

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Gengraf (Capsules, Modified), Gengraf

What is Gengraf Capsules?

Ranolazine ER Tablets

Generic Name: ranolazine

Brand name: Ranexa

Synonyms: Ranolazine

What is Ranolazine ER Tablets?